Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Orchestra BioMed Holdings, Inc. - Ordinary Shares (NQ:OBIO)

3.340 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Orchestra BioMed Holdings, Inc. - Ordinary Shares

< Previous 1 2 Next >
Sidoti Events, LLC's Virtual May Micro-Cap Conference
Via ACCESS Newswire
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed’s AVIM Therapy Global Intellectual Property Estate Reaches 137 Issued Patents for the Treatment of Hypertension and Heart Failure
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Receives FDA Approval of IDE to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-AngioInfusion Balloon, Virtue SAB, Head-to-Head with Paclitaxel-Coated Balloon
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces AVIM Therapy-Focused Satellite Symposium at HRS 2025 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
SmallCaps Gaining Momentum: TIVC, GELS, SLI, OBIO in Healthcare, Biotech, Energy, Military Defense, Etc. – More Stocks Inside
Via AB Newswire
Topics Government
Exposures Political Product Safety
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Present at Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Jefferies London Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Precision Neuroscience Expands Executive Team as Brain–Computer Interface Industry Rapidly Advances
Jayme Strauss and Mike Kaswan join as Chief Clinical and Commercial Officer and Chief Financial Officer, respectively, as the company progresses toward FDA clearance 
From Precision Neuroscience
Via GlobeNewswire
Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed to Participate in Upcoming Investor Conferences
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
From Orchestra BioMed Holdings, Inc.
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.